Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Fosun Pharma and SIMM to Co-Develop Oncology Drug

publication date: Nov 27, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Fosun Pharma and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, have agreed to jointly develop an innovative, small-molecule, triple-target oncology drug. The two entities will share the risk, the patent and benefits, though specific details of the arrangement were not disclosed. Fosun’s share of the research will be carried out by Chongqing Fochon Pharma, a subsidiary founded in 2009 by Dr. Weibo Wang. More details....

Stock Symbol: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors